![Frontiers | Shabyar Ameliorates High Glucose Induced Retinal Pigment Epithelium Injury Through Suppressing Aldose Reductase and AMPK/mTOR/ULK1 Autophagy Pathway Frontiers | Shabyar Ameliorates High Glucose Induced Retinal Pigment Epithelium Injury Through Suppressing Aldose Reductase and AMPK/mTOR/ULK1 Autophagy Pathway](https://www.frontiersin.org/files/Articles/852945/fphar-13-852945-HTML/image_m/fphar-13-852945-g006.jpg)
Frontiers | Shabyar Ameliorates High Glucose Induced Retinal Pigment Epithelium Injury Through Suppressing Aldose Reductase and AMPK/mTOR/ULK1 Autophagy Pathway
![Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - European Urology Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - European Urology](https://www.europeanurology.com/cms/asset/81f18467-6fce-4034-916c-218ba81825cf/gr2.jpg)
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - European Urology
![Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial - The Lancet Oncology Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/cd0dc984-e8b0-47c2-8fde-e4b6934cd219/gr1.gif)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial - The Lancet Oncology
![Frontiers | Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease Frontiers | Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease](https://www.frontiersin.org/files/Articles/970199/fonc-12-970199-HTML/image_m/fonc-12-970199-g001.jpg)
Frontiers | Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease
![An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer | Nature Medicine An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01317-6/MediaObjects/41591_2021_1317_Fig1_HTML.png)
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer | Nature Medicine
![Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -](https://www.thelancet.com/cms/attachment/3c4fe8b1-e2b1-4f4a-9ae1-9ac716671d29/gr2_lrg.jpg)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/9b4180f6-0d2e-4631-b126-8a4a309031e5/gr2_lrg.jpg)